Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Spero Therapeutics, Inc. (SPRO)

Spero Therapeutics Q2 net loss $9.6 million; no revenue vs. $14.2 million a year ago

Negative Impact 4 of 5 earnings Written later

Spero Therapeutics reported a second-quarter 2026 net loss of $9.6 million, or $0.16 per share, compared with a net loss of $1.7 million, or $0.03 per share, a year earlier. The company recognized no revenue in the quarter, versus $14.2 million in the second quarter of 2025, and said it expects cash plus the July 2026 royalty financing to fund operations into the second half of 2029.

Key points

  • Q2 2026 total revenue was zero, compared with $14.2 million in Q2 2025, as deferred and grant revenue had been fully recognized in prior periods.
  • Q2 2026 research and development expense was $3.4 million, down from $10.7 million; general and administrative expense rose to $6.5 million from $5.9 million.
  • Cash and cash equivalents were $50.8 million at June 30, 2026, before the $105 million royalty financing closed in July 2026.
  • Other events disclosed include the July 2026 exclusive license for SP001 from Innovent Biologics and the appointment of Debra Jeske Zack as Chief Medical Officer.

The filing

CompanySpero Therapeutics, Inc. (SPRO)
Form8-K, current report
Filed with the SECAug 12, 2026, 4:09 PM ET
Accession number0001193125-26-346855

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 12, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.